fluidIQ
Matt Vogelhuber serves as the Chief Executive Officer at fluidIQ, a medical devices company focused on improving quality of life through fluidic solutions, since December 2020. Concurrently, Vogelhuber has been involved in business development with Kringle Pharma and as Principal and Managing Partner at PerimeterPHARMA Solutions, LLC, specializing in commercialization strategies and alliance management in the pharma and biotech sectors. Previous leadership roles include Director at Aegle Therapeutics, East Coast/South Central Oncology Sales Director at Myriad Genetics, President and CEO at Concordant Pharmaceuticals, and various positions at Eli Lilly and Company, including Sales Director overseeing significant annual sales and operational budgets. Vogelhuber holds degrees from the University of Pittsburgh, The Ohio State University, Louisiana State University, and the University of Miami.
This person is not in any teams
This person is not in any offices
fluidIQ
We are fluidIQ: a multi-disciplinary team that has the expertise to solve complex problems, a passion to make a positive impact in our world, and a sense of urgency to bring hope to the human race. fluidIQ is a public benefit and Delaware corporation. We provide simple yet elegant solutions based on proprietary fluidics technology. The company was founded by a group of doctors, engineers, and patient advocates who joined together to find solutions for gaps in medical needs, including ventilators, during in the midst of the coronavirus-caused world crisis. fluidIQ aims to deliver hope to a world in need with simple, easy-to-deploy technology solutions that solve the most pressing medical challenges of our time. fluidIQ’s roadmap for an entire family of products is based on its proprietary platform of fluidics-operated devices dedicated to filing gaps in emergency and preparedness protocols that are user-friendly, scalable and cost-effective. Quick video overview: https://youtu.be/LYyx_HjmWcY